December 19, 2018
Authored and Edited by Megan L. Meyers; M. Andrew Holtman, Ph.D.
On December 11, 2018, FDA issued its fifth final guidance document related to the development of biosimilars and interchangeability products entitled Questions and Answers on Biosimilar Development and the BPCI Act, as well as its fourth draft guidance document on the same topic, entitled New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2).
Both documents provide answers to common questions from prospective applicants and other parties regarding BPCIA. They are intended to enhance transparency and facilitate development and approval of proposed biosimilars and interchangeable biosimilars, as well as describe FDA’s interpretation of certain statutory requirements added by BPCIA.
The final and draft guidance documents dedicate their largest sections to questions and answers related to biosimilarity or interchangeability. Generally, they cover (1) sponsor contact with FDA to discuss its proposed development program, (2) biosimilar product characteristics and requirements, and (3) questions and answers on requirements for obtaining licensure. The concluding two sections in each document relate to requirements to submit a BLA for a “biological product,” which covers “product class” definition and submission of a marketing application for a proposed antibody-drug conjugate, and exclusivity, which provides answers to questions regarding reference product exclusivity and unexpired orphan exclusivity.
Readers are encouraged to read the final guidance.
abbreviated biologic license application (aBLA), Biologic License Application (BLA), Biologics Price Competition and Innovation Act (BPCIA), FDA Guidance, Food and Drug Administration (FDA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.